Livedoid vasculitis - Vasculitis Livedoid
Vasculitis Livedoid (Livedoid vasculitis) jẹ arun ara onibaje tí a máa ń rí jùlọ ní àárín àwọn ọdọ àti àwọn obìnrin tó ti dàgbà. Acronym kan tí a ń lò láti ṣàpèjúwe àfihàn rẹ ni “Awọn ọgbẹ purpuric irora pẹlu apẹrẹ reticular ti awọn opin isalẹ” (PURPLE). Ó ní í ṣe pẹ̀lú ọ̀pọ̀ àrùn, pẹ̀lú haipatensonu iṣọn‑ẹjẹ onibaje àti varicosities.
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ó lè wá pẹ̀lú irora.
relevance score : -100.0%
ReferencesLivedoid vasculopathy jẹ ipo awọ to ṣọwọn ti o farahan nipasẹ awọn ọgbẹ irora ti o ma n pada wa ni awọn ẹsẹ isalẹ.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy jẹ arun awọ to ṣọwọn ti o fa awọn adaijina loorekoore lori awọn ẹsẹ isalẹ, ti o fi silẹ lẹhin awọn aleebu didan ti a mọ si atrophie blanche. Bí ó tilẹ̀ jẹ́ pé àǹfààní tó dájú kò tíì ṣíwájú, a ro pé ìdí tí ẹ̀jẹ̀ ń dín pọ̀ (hypercoagulability) ni àǹfààní pàtàkì, pẹ̀lú ìgbóná gẹ́gẹ́ bí àǹfààní kejì. Àwọn ohun tí ń ṣe àfikún sí ìdí yìí ni: deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Nínú àwọn biopsies, a rí ìdí tí ẹ̀jẹ̀ ń dín pọ̀ nínú àwọn ohun èlò, pẹ̀lú ìkúnra àwọn odi àgbá, àti àìlera. Ìtọ́jú ń dojú kọ́ àìlera yìí nípa fífi ojú kọ́ ìdènà ìdí ẹ̀jẹ̀ pẹ̀lú àwọn oogun bíi egboogi‑platelet, àwọn tinrin ẹ̀jẹ̀, àti itọju fibrinolytic. Àwọn oogun míì tí a lè lo fún àìlera awọ ara ni: colchicine, hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy jẹ ipo ti o ṣọwọn, ti o nfa awọn egbo lori awọn ẹsẹ mejeeji. Ipilẹṣẹ ti awọn didi ẹjẹ ninu awọn ohun elo ẹjẹ kekere ni a ro pe o fa nipasẹ didi ti o pọ si ati idinku idinku, pẹlu ibajẹ si awọ inu ọkọ. O wọpọ julọ laarin awọn obinrin, paapaa laarin ọjọ‑ori 15 si 50. Didi siga mimu duro, itọju awọn ọgbẹ, ati lilo awọn oogun bii awọn tinrin ẹjẹ ati awọn oogun antiplatelet ti munadoko.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
